Sunbird: blood-based diagnostics via exosomes and proteases

Sunbird is betting exosomes will provide a better window into amyloid aggregation in the brain than other blood-based diagnostics for Alzheimer's disease. The biotech aims to partner the test for use in response monitoring in clinical trials, and plans to roll it out as a diagnostic in 2025.

Formed in 2021, Sunbird Bio Inc. is the result of a merger between Sunbird Bio Pte. Ltd., a Singaporean company backed by ClavystBio, Polaris Partners and Section 32, and Glympse Bio Inc., which was also backed by Polaris, along with Singaporean firm Temasek. Glympse had raised at least $75 million in venture funds since its founding in 2015...